SPONSOR
Abramson Cancer Center at Penn Medicine
Total Trials
19
Recruiting
19
Phases
EARLY_Phase 1, Phase 1, Phase 2
Conditions studied: Endometrial CancerNear Infrared Fluorescence ImagingCYTALUX (Pafolacianine) InjectionPlanned Diagnostic LaparoscopiesBreast CancerNeoplasiaER Positive Breast CancerHER2-negative Breast CancerTNBC - Triple-Negative Breast CancerKidney Neoplasm
Abramson Cancer Center at Penn Medicine is a clinical research sponsor with 19 registered studies on ClinicalTrials.gov, of which 19 are actively recruiting participants. Research covers conditions including Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies.
The trial portfolio spans EARLY_Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Abramson Cancer Center at Penn Medicine
How many clinical trials has Abramson Cancer Center at Penn Medicine sponsored?
ClinicalMetric currently tracks 19 clinical trials sponsored by Abramson Cancer Center at Penn Medicine, of which 19 are actively recruiting participants. These trials cover conditions including Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Abramson Cancer Center at Penn Medicine research focus on?
Abramson Cancer Center at Penn Medicine clinical trials span Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies, Breast Cancer, and additional conditions. The research pipeline includes EARLY_Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Abramson Cancer Center at Penn Medicine clinical trial?
To participate in a Abramson Cancer Center at Penn Medicine trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Abramson Cancer Center at Penn Medicine trials with current recruitment status updated daily.
Clinical Trials by Abramson Cancer Center at Penn Medicine
NCT07278986 EARLY_Phase 1
Recruiting
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Endometrial Cancer
NCT03863457 Phase 1
Recruiting
[18F] F-GLN by PET/CT in Breast Cancer
Breast Cancer
NCT01577251
Recruiting
The Radiation Oncology Registry and Biosample Repository
Neoplasia
NCT05396612
Recruiting
Role of the Immune Environment in Response to Therapy in Breast Cancer
Breast Cancer
NCT02346435
Recruiting
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Kidney Neoplasm
NCT02732171
Recruiting
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
Breast Cancer
NCT05496036 Phase 2
Recruiting
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Merkel Cell Carcinoma
NCT06747845 Phase 2
Recruiting
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
Pancreatic Adenocarcinoma Metastatic
NCT03546829 Phase 1
Recruiting
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
Early Stage Non-Small Cell Lung Cancer
NCT07222241
Recruiting
Comparing Numbing Techniques in Mohs Micrographic Surgery
Skin Cancer Face
NCT04339036 Phase 2
Recruiting
CapTemY90 for Grade 2/3 NET Liver Metastases
Neuroendocrine Tumor Grade 2
NCT07471958
Recruiting
Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)
Cancer
NCT04523857 Phase 2
Recruiting
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Breast Cancer
NCT05659797 EARLY_Phase 1
Recruiting
FES BPET-DBT in Newly Diagnosed Breast Cancer
Breast Cancer
NCT05916196 Phase 2
Recruiting
[18F]FES PET/.CT in Uterine Cancer
Uterine Cancer
NCT07147179
Recruiting
Short Course Radiotherapy
Central Nervous System Cancer
NCT02637934 Phase 1
Recruiting
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07082439 Phase 2
Recruiting
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Colorectal Adenocarcinoma Metastatic in the Liver
NCT07715188
Recruiting
Low Dose Radiotherapy for Osteoarthritis
Osteoarthitis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology